Cover Image

Editorial: New Insights Into the Aetiopathogenesis of Post‐Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next? Authors' Reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Mohamed H. Eldesouki, Swapna Gayam
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients
by: Mohamed H. Eldesouki, et al.
Published: (2026)

Letter: Gastroparesis in Lung Transplantation: Time to Reframe and Standardize Post‐Transplant Foregut Motility Evaluation: Authors' Reply
by: Mohamed H. Eldesouki, et al.
Published: (2026)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
by: Kee Huat Chuah, et al.
Published: (2025)

Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply
by: E. Coss‐Adame, et al.
Published: (2026)

Stability of Classification Systems for Irritable Bowel Syndrome
by: Mais Khasawneh, et al.
Published: (2025)

Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome
by: Mohsin F. Butt, et al.
Published: (2024)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
by: Eric Lawitz, et al.
Published: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
by: Kee Huat Chuah, et al.
Published: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
by: Fai Fai Ho, et al.
Published: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
by: Suprabhat Giri, et al.
Published: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
by: Bharati Kochar, et al.
Published: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
by: Jessica A. Fitzpatrick, et al.
Published: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
by: Cristina Rubín de Célix, et al.
Published: (2025)

Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome
by: Andrea Shin, et al.
Published: (2025)

Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
by: Vivek C. Goodoory, et al.
Published: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System
by: Neil S. Zheng, et al.
Published: (2025)

Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom
by: Mohsin F. Butt, et al.
Published: (2025)

Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care
by: Vivek C. Goodoory, et al.
Published: (2026)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
by: Aurelien Amiot, et al.
Published: (2025)

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance
by: T. E. Conley, et al.
Published: (2026)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
by: Mathieu Uzzan, et al.
Published: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
by: A. B. Fons, et al.
Published: (2026)

Editorial: Heads or Tails in the Treatment of Functional Dyspepsia—Does the Side of the Coin Matter?
by: Cedric Van de Bruaene, et al.
Published: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
by: Kyle Staller, et al.
Published: (2024)

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC. Authors' Reply
by: Natassia Tan, et al.
Published: (2025)

Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome
by: Lesley A. Houghton, et al.
Published: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
by: Isabel Carbery, et al.
Published: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
by: Jianhui Zhao, et al.
Published: (2024)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
by: Monica E. W. Derks, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
by: A. B. Fons, et al.
Published: (2026)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
by: Sanjay K. Murthy
Published: (2026)

Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’. Authors' Reply
by: Hermann Brenner, et al.
Published: (2025)

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
by: Olga P. Nyssen, et al.
Published: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
by: Ramin Ebrahimi, et al.
Published: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
by: Simone Chin, et al.
Published: (2025)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
by: Jeongkuk Seo, et al.
Published: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
by: Máté Szilcz, et al.
Published: (2025)